Updated clinical recommendations for the use of tibolone in Asian women

References

• Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas 2004;48(Suppl 1):S1–S3
   PubMedGoogle Scholar
• Gompel A, Chaouat M, Jacob D, et al In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351–359
   PubMed Web of Science ®Google Scholar
• Hammar M, Christau S, Nathorst-Boos J, et al A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904–911
   PubMedGoogle Scholar
• Huber J, Palacios S, Berglund L, et al Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886–893
   Google Scholar
• Baracat EC, Barbosa IC, Giordano MG, et al A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002;5:60–69
   PubMed Web of Science ®Google Scholar
• Nathorst-Boos J, Hammar M. Effect on sexual life – a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15–20
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Vicente JJ, Figueras F, et al Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161–168
   PubMed Web of Science ®Google Scholar
• Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, et al Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646–656
   PubMed Web of Science ®Google Scholar
• Egarter C, Topcuoglu A, Vogl S, et al Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women. Acta Obstet Gynecol Scand 2002;81:649–653
   PubMed Web of Science ®Google Scholar
• Somunkiran A, Erel CT, Demirci F, et al The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study. Maturitas 2007;56:61–68
   PubMed Web of Science ®Google Scholar
• Egarter C, Sator M, Berghammer P, et al Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet 1999;64:281–286
   PubMed Web of Science ®Google Scholar
• Meeuwsen IB, Samson MM, Duursma SA, et al The effect of tibolone on fat mass, fat-free mass, and total body water in postmenopausal women. Endocrinology 2001;142:4813–4817
   PubMed Web of Science ®Google Scholar
• Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4:203–208
   PubMedGoogle Scholar
• Wender MC, Edelweiss MI, Campos LS, et al Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause 2004;11:423–429
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Raffaelli R, et al A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 2000;88:91–94
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708
   PubMed Web of Science ®Google Scholar
• Lundström E, Christow A, Kersemaekers W, et al Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717–722
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, et al Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–146
   PubMed Web of Science ®Google Scholar
• Boulet MJ, Oddens BJ, Lehert P, et al Climacteric and menopause in seven South-east Asian countries. Maturitas 1994;19:157–176
   PubMed Web of Science ®Google Scholar
• Huang KE, Ling X, Jaisamram U, et al A multinational survey of Asian menopausal women. Presented at XVIII FIGO World Congress of Gynaecology and Obstetrics; 2006, Kuala Lumpur, Malaysia
   Google Scholar
• Asia Pacific Menopause Federation. Asia-Pacific Menopause Federation consensus statement on the management of the menopause, April 2008. Available at: www.apmf.net/
   Google Scholar
• Speroff L, Kenemans P, Burger HG. Practical guidelines for postmenopausal hormone therapy. Maturitas 2005;51:4–7
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, Birkhauser MH, et al IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–194
   PubMed Web of Science ®Google Scholar
• Utian WH, Archer DF, Bachmann GA, et al Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584–602
   PubMed Web of Science ®Google Scholar
• Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21–28
   PubMed Web of Science ®Google Scholar
• Haines CJ, Rong L, Chung TK, et al The perception of the menopause and the climacteric among women in Hong Kong and southern China. Prev Med 1995;24:245–248
   PubMed Web of Science ®Google Scholar
• Haines CJ, Xing SM, Park KH, et al Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 2005;52:264–276
   PubMed Web of Science ®Google Scholar
• Pan HA, Wu MH, Hsu CC, et al The perception of menopause among women in Taiwan. Maturitas 2002;41:269–274
   PubMed Web of Science ®Google Scholar
• Zhao G, Wang L, Yan R, et al Menopausal symptoms: experience of Chinese women. Climacteric 2000;3:135–144
   PubMedGoogle Scholar
• Choi H, Lee HK, Park HM. The Korean menopausal women's attitudes and awareness on menopause. J Korean Soc Menopause 2003;9:36–43
   PubMedGoogle Scholar
• Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197–214
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Schneider HP, Panay N, et al The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol 2006;22:369–375
   PubMed Web of Science ®Google Scholar
• Dhillon HK, Singh HJ, Ghaffar NA. Sexual function in menopausal women in Kelantan, Malaysia. Maturitas 2005;52:256–263
   PubMed Web of Science ®Google Scholar
• Hammar ML, van de Weijer P, Franke HR, et al Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. Br J Obstet Gynaecol 2007;114:1522–1529
   Google Scholar
• Archer DF, Hendrix S, Gallagher JC, et al Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911–918
   PubMed Web of Science ®Google Scholar
• Delmas PD, Davis SR, Hensen J, et al Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int 2008;19:1153–1160
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'aniello S, Garbe E, et al Hormone replacement therapy use and the risk of stroke. Maturitas 2008;61:305–309
   PubMed Web of Science ®Google Scholar
• Bots ML, Evans GW, Riley W, et al The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746–755
   PubMed Web of Science ®Google Scholar
• Clarkson TB. Does tibolone exacerbate atherosclerosis? Eur Heart J 2006;27:635–637
   PubMed Web of Science ®Google Scholar
• Lokkegaard E, Andreasen AH, Jacobsen RK, et al Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660–2668
   PubMed Web of Science ®Google Scholar
• Opatrny L, Dell'Aniello S, Assouline S, et al Hormone replacement therapy use and variations in the risk of breast cancer. Br J Obstet Gynaecol 2008;115:169–175; discussion 175
   Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–427
   PubMed Web of Science ®Google Scholar
• Pan HA, Wang ST, Pai MC, et al Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. J Reprod Med 2003;48:375–380
   PubMed Web of Science ®Google Scholar
• Wu MH, Pan HA, Wang ST, et al Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001;4:314–319
   PubMedGoogle Scholar
• Yang TS, Tsan SH, Chen CR, et al Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. Chinese Med J (Taipei) 1999;62:308–315
   Google Scholar
• Lam PM, Cheung GW, Shek DT, et al A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses. Menopause 2004;11:416–422
   PubMed Web of Science ®Google Scholar
• Koh KK, Ahn JY, Jin DK, et al Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003;23:1889–1894
   PubMed Web of Science ®Google Scholar
• White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009;123(Suppl 4):S11–S17
   PubMed Web of Science ®Google Scholar
• Tan KS, Rashid A, Tan CT. Venous thromboembolism in ischaemic stroke in Asia. Neurol Asia 2008;13:95–101
   Web of Science ®Google Scholar
• Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005;3:1611–1617
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Sie A, et al Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262–269
   PubMed Web of Science ®Google Scholar
• Habel LA, Capra AM, Oestreicher N, et al Mammographic density in a multiethnic cohort. Menopause 2007;14:891–899
   PubMed Web of Science ®Google Scholar
• Valdivia I, Campodonico I, Tapia A, et al Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617–623
   PubMed Web of Science ®Google Scholar
• Bruce D, Robinson J, McWilliams S, et al Long-term effects of tibolone on mammographic density. Fertil Steril 2004;82:1343–1347
   PubMed Web of Science ®Google Scholar
• Howick J, Phillips B, Ball C, et al Oxford Centre for Evidence-based Medicine Levels of Evidence. Oxford Centre for Evidence-based Medicine Levels of Evidence. 2009. Available at: http://www.cebm.net/index.aspx?o=1025
   Google Scholar
• Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543–1551
   PubMed Web of Science ®Google Scholar
• de Vries CS, Bromley SE, Thomas H, et al Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Safety 2005;28:241–219
   PubMed Web of Science ®Google Scholar
• Koh LK, Sedrine WB, Torrelba TP, et al A simple tool to identify Asian Women at increased risk of osteoporosis. Osteoporos Int 2001;12:699–705
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385–397
   PubMed Web of Science ®Google Scholar
• Chow SN, Huang CC, Lee YT. Demographic characteristics and medical aspects of menopausal women in Taiwan. J Formos Med Assoc 1997;96:806–811
   PubMed Web of Science ®Google Scholar
• Nijland EA, Nathorst-Boos J, Palacios S, et al Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12:114–121
   PubMed Web of Science ®Google Scholar
• Nijland EA, Weijmar Schultz WC, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas 2007;58:164–173
   PubMed Web of Science ®Google Scholar